CN104138380B - 厄洛替尼或其可药用盐的组合物及其制备方法和用途 - Google Patents
厄洛替尼或其可药用盐的组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN104138380B CN104138380B CN201310169676.9A CN201310169676A CN104138380B CN 104138380 B CN104138380 B CN 104138380B CN 201310169676 A CN201310169676 A CN 201310169676A CN 104138380 B CN104138380 B CN 104138380B
- Authority
- CN
- China
- Prior art keywords
- tarceva
- weight
- tablet
- pharmaceutical composition
- officinal salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
活性成分 | 164g |
乳糖 | 103.8g |
微晶纤维素 | 132.7g |
羧甲淀粉钠 | 36g |
十二烷基硫酸钠 | 4.5g |
硬脂酸镁 | 9g |
活性成分 | 164g |
预胶化淀粉 | 103.8g |
乳糖 | 132.7g |
羧甲淀粉钠 | 36g |
十二烷基硫酸钠 | 4.5g |
硬脂酸镁 | 9g |
活性成分 | 164g |
预胶化淀粉 | 95.8g |
微晶纤维素 | 140.7g |
羧甲淀粉钠 | 36g |
泊洛沙姆 | 4.5g |
硬脂酸镁 | 9g |
活性成分 | 164g |
预胶化淀粉 | 120g |
微晶纤维素 | 116.5g |
羧甲淀粉钠 | 36g |
泊洛沙姆 | 4.5g |
硬脂酸镁 | 9g |
活性成分 | 164g |
预胶化淀粉 | 112.4g |
微晶纤维素 | 127.5g |
羧甲淀粉钠 | 36g |
泊洛沙姆 | 4.5g |
硬脂酸镁 | 5.6g |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310169676.9A CN104138380B (zh) | 2013-05-09 | 2013-05-09 | 厄洛替尼或其可药用盐的组合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310169676.9A CN104138380B (zh) | 2013-05-09 | 2013-05-09 | 厄洛替尼或其可药用盐的组合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104138380A CN104138380A (zh) | 2014-11-12 |
CN104138380B true CN104138380B (zh) | 2018-07-13 |
Family
ID=51847833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310169676.9A Active CN104138380B (zh) | 2013-05-09 | 2013-05-09 | 厄洛替尼或其可药用盐的组合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104138380B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105362239A (zh) * | 2014-09-01 | 2016-03-02 | 深圳信立泰药业股份有限公司 | 一种含有盐酸厄洛替尼的药物组合物及其制备方法 |
CN105168172A (zh) * | 2015-08-26 | 2015-12-23 | 浙江华义医药有限公司 | 一种改善溶出度和稳定性的盐酸厄洛替尼片及其制备方法 |
CN111184698A (zh) * | 2018-11-15 | 2020-05-22 | 和记黄埔医药(上海)有限公司 | 呋喹替尼制剂及其应用 |
CN109602715A (zh) * | 2019-02-21 | 2019-04-12 | 江苏豪森药业集团有限公司 | 盐酸厄洛替尼片剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101016266A (zh) * | 2005-01-12 | 2007-08-15 | 美德(江西)生物科技有限公司 | 无结晶型态的盐酸埃罗替尼以及其分散组合物 |
CN101300015A (zh) * | 2005-11-04 | 2008-11-05 | 默克公司 | 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法 |
WO2009070546A1 (en) * | 2007-11-28 | 2009-06-04 | Tragara Pharmaceuticals, Inc. | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders |
US20120022256A1 (en) * | 2007-08-17 | 2012-01-26 | Hetero Drugs Limited | Novel Hydrated Form of Erlotinib Free Base and a Process For Preparation Of Erlotinib Hydrochloride Polymorph Form A Substantially Free of Polymorph Form B |
-
2013
- 2013-05-09 CN CN201310169676.9A patent/CN104138380B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101016266A (zh) * | 2005-01-12 | 2007-08-15 | 美德(江西)生物科技有限公司 | 无结晶型态的盐酸埃罗替尼以及其分散组合物 |
CN101300015A (zh) * | 2005-11-04 | 2008-11-05 | 默克公司 | 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法 |
US20120022256A1 (en) * | 2007-08-17 | 2012-01-26 | Hetero Drugs Limited | Novel Hydrated Form of Erlotinib Free Base and a Process For Preparation Of Erlotinib Hydrochloride Polymorph Form A Substantially Free of Polymorph Form B |
WO2009070546A1 (en) * | 2007-11-28 | 2009-06-04 | Tragara Pharmaceuticals, Inc. | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders |
Also Published As
Publication number | Publication date |
---|---|
CN104138380A (zh) | 2014-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2739153T3 (en) | TREATMENT OF BREAST CANCER | |
TW201615191A (zh) | 氨氯地平藥物應用於癌症治療 | |
CN105663064B (zh) | 一种甲磺酸伊马替尼胃溶型微丸片及其制备方法 | |
CN104138380B (zh) | 厄洛替尼或其可药用盐的组合物及其制备方法和用途 | |
CN103006608B (zh) | 一种含有吉非替尼的药物组合物 | |
RU2739992C2 (ru) | Композиции апилимода и способы их применения в лечении колоректального рака | |
AU2016297555A1 (en) | Methods for treating cancer using apilimod | |
US20210015787A1 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
Liu et al. | Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial | |
JP2023022190A (ja) | 癌治療 | |
US20220362209A1 (en) | Methods and compositions for treating chemotherapy-induced diarrhea | |
CN109073650A (zh) | 包括对西地尼布进行固定的间歇给药的方法 | |
TW202028194A (zh) | 呋喹替尼製劑及其應用 | |
CA2872677C (en) | Treating pain in patients with hepatic impairment | |
CN107530332B (zh) | 一种含有吡咯并六元杂环化合物或其可药用盐的药物组合物的制备方法 | |
CN107073015A (zh) | 用于治疗吸烟者中的非小细胞肺癌的维利帕尼与卡铂和紫杉醇的组合 | |
WO2020233710A1 (zh) | 吡啶胺化合物的药物组合物及其在ros1阳性非小细胞肺癌中的应用 | |
AU2020454132A1 (en) | Methods and compositions for treating chemotherapy-induced diarrhea | |
TWI709402B (zh) | 西達本胺與依西美坦在製備用於治療乳腺癌的聯合用藥物中的用途及聯合用藥物 | |
CN107530331B (zh) | 一种含有吡咯并六元杂环化合物或其可药用盐的药物组合物 | |
CN114340625A (zh) | 用雌激素受体-α抑制剂的口服剂型治疗癌症的方法 | |
Chaturvedi et al. | Comparative Evaluation Of Natural And Semisynthetic Superdisintegrants In The Formulation Of Orodispersible Tablets of Norfloxacin | |
CN112533600B (zh) | 用于治疗小细胞肺癌的喹啉衍生物 | |
CN102824341A (zh) | 没食子儿茶素在制备抗良性前列腺增生药物中的应用 | |
CN103860486A (zh) | 一种来曲唑口腔崩解片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information |
Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB02 | Change of applicant information |
Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: Jiangsu best Pharmaceutical Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: Jiangsu best Pharmaceutical Co.,Ltd. Applicant after: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160318 Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Applicant before: Lianyungang Hongchuang Pharmaceutical Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |